Trend, disparities, and projection analysis of public data on foot fractures in Sweden: a retrospective analysis of 179 129 fractures.

Publication date: Jul 27, 2024

Orthopedic injuries to the foot constitute a significant portion of lower extremity injuries, necessitating an understanding of trends for effective preventive strategies and resource allocation. Demographic shifts, improved traffic safety, and lifelong physical activity may alter incidence rates, trauma mechanisms, and fracture distribution. This study explores the prevalence of foot fractures in Sweden using publicly available data. Utilizing data from the Swedish National Board of Health and Welfare (SNBHW) spanning 2008-2022, retrospective study focuses on foot fractures in Sweden. Analysis includes calculating annual incidence rates per 100,000 person-years, assessing temporal trends, and exploring seasonal variations. Poisson regression analysis was used for projections into 2035. Between 2008-2022, the average annual foot fracture incidence was 11,942, with notable fluctuations influenced by the COVID-19 pandemic. Age and sex disparities impact rates, and seasonal variance highlights increased incidence in summer. By 2035, foot fractures will decreasae amongst several demographic groups. This study provides insights into temporal trends, sex differences, and seasonal variations foot fracture patterns in Sweden. The identified trends suggest the utilization of targeted preventive strategies, efficient resource allocation, and informed healthcare planning. Despite limitations, this research offers valuable insights into foot fractures within the Swedish population, utilizing publicly aggregated data.

Open Access PDF

Concepts Keywords
Healthcare Adolescent
Pandemic Adult
Sweden Aged
Aged, 80 and over
Child
Child, Preschool
COVID-19
Epidemiology
Female
Foot fractures
Foot Injuries
Fractures, Bone
Humans
Incidence
Infant
Infant, Newborn
Male
Middle Aged
Prevalence
Preventive measures
Retrospective Studies
Seasons
Sweden
Trends
Young Adult

Semantics

Type Source Name
disease VO effective
disease VO Optaflu
disease MESH COVID-19 pandemic
disease VO age
disease VO efficient
disease VO population
disease IDO quality
drug DRUGBANK Isoxaflutole
drug DRUGBANK L-Valine
disease IDO intervention
disease MESH death
disease VO report
disease VO SWE vaccine adjuvant
disease VO monthly
drug DRUGBANK Fenamole
disease MESH infection
disease MESH complications
disease VO USA
disease MESH osteoporosis
drug DRUGBANK Trestolone
disease IDO country
drug DRUGBANK Caffeine
drug DRUGBANK Aspartame
drug DRUGBANK Elm
disease VO adult age

Original Article

(Visited 1 times, 1 visits today)